Literature DB >> 20027603

Enhanced expression of proproliferative and antiapoptotic genes in ulcerative colitis-associated neoplasia.

Jirí Svec1, Jana Musílková, Jana Bryndová, Tomás Jirásek, Václav Mandys, Milan Kment, Jirí Pácha.   

Abstract

BACKGROUND: Inflammatory bowel diseases including long-standing ulcerative colitis (UC) have an increased risk of evolving into colorectal cancer (CRC). The overexpression of some proproliferative and antiapoptotic genes, such as survivin, telomerase catalytic subunit (hTERT), integrin-linked kinase (ILK), and regulatory factors c-MYB and Tcf-4, has been implicated in the development and progression of several human malignancies including CRC.
METHODS: In this study we analyzed the expression alterations of these markers and proinflammatory enzymes cyclooxygenase 2 (COX-2) and inducible nitric oxide synthase (iNOS) during the transition of colonic mucosa from chronic inflammation to epithelial neoplasia in biopsies of UC patients using quantitative real-time polymerase chain reaction and immunohistochemistry; additionally, we compared the expression profiles of this gene panel in samples of patients with CRC after tumor resection and in human tumor xenografts of SW620 malignant colonic cells.
RESULTS: The transcript levels of survivin, c-MYB, COX-2, iNOS, and Tcf-4 showed a statistically significant increase during neoplastic transformation of UC patient colonic mucosa, whereas hTERT and ILK were not elevated. In contrast, the specimens of CRC showed upregulated expression of not only survivin, c-MYB, Tcf-4, COX-2, and iNOS but also hTERT. A similar expression profile was observed in human tumor xenografts in which all transcripts with the exception of c-MYB were upregulated.
CONCLUSIONS: These results suggest that telomerase and ILK activation occurs during the later stages of carcinoma progression, whereas upregulation of survivin, c-MYB, and Tcf-4 is a feature of the early stage of development of neoplasia, and thus, they might serve as early indicators for UC-associated colorectal carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20027603     DOI: 10.1002/ibd.21178

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  5 in total

1.  miR-143 and miR-145 are downregulated in ulcerative colitis: putative regulators of inflammation and protooncogenes.

Authors:  Joel R Pekow; Urszula Dougherty; Reba Mustafi; Hongyan Zhu; Masha Kocherginsky; David T Rubin; Stephen B Hanauer; John Hart; Eugene B Chang; Alessandro Fichera; Loren J Joseph; Marc Bissonnette
Journal:  Inflamm Bowel Dis       Date:  2011-05-06       Impact factor: 5.325

2.  Gene signature distinguishes patients with chronic ulcerative colitis harboring remote neoplastic lesions.

Authors:  Joel Pekow; Urszula Dougherty; Yong Huang; Edward Gometz; Jeff Nathanson; Greg Cohen; Shawn Levy; Masha Kocherginsky; Nanda Venu; Maria Westerhoff; John Hart; Amy E Noffsinger; Stephen B Hanauer; Roger D Hurst; Alessandro Fichera; Loren J Joseph; Qiang Liu; Marc Bissonnette
Journal:  Inflamm Bowel Dis       Date:  2013-03       Impact factor: 5.325

Review 3.  Inflammatory colonic carcinogenesis: a review on pathogenesis and immunosurveillance mechanisms in ulcerative colitis.

Authors:  Marco Scarpa; Ignazio Castagliuolo; Carlo Castoro; Anna Pozza; Melania Scarpa; Andromachi Kotsafti; Imerio Angriman
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

Review 4.  MicroRNA in inflammatory bowel disease: Translational research and clinical implication.

Authors:  Kurt Fisher; Jingmei Lin
Journal:  World J Gastroenterol       Date:  2015-11-21       Impact factor: 5.742

5.  Immunohistochemical expression of proinflammatory enzyme COX-2 and p53 in ulcerative colitis and its associated dysplasia and colorectal carcinoma.

Authors:  Nehal Mohamed Elmashad; Dina H Ziada; Eiman A Hasby; Abd El Motaleb Mohamed
Journal:  J Microsc Ultrastruct       Date:  2016-03-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.